The study titled “Effects of a standardized guggulsterone phosphate supplement on body composition in overweight adults: A pilot study” aims to investigate the potential effects of a guggulsterone phosphate salt compound on the body composition and mood states of overweight adults. This double-masked, randomized, placebo-controlled study involved 20 participants with a body-mass index (BMI) greater than 25 kg/m2, dividing them into three groups: the experimental group receiving guggulsterones and phosphate, the placebo group, and the control group.

The experimental group received a daily dosage of 750 mg of guggulsterones and 1650 mg of phosphate for a period of six weeks. The placebo group was administered maltodextrin capsules, while the control group received no treatment. Participants were instructed to adhere to the American Heart Association Step One diet and engage in a 3-day-per-week circuit exercise program throughout the study period.

The study observed a significant decrease in body weight (3.2%, P < 0.05) and fat mass (20.6%) in the experimental group, along with a notable decrease in fatigue levels (63.7%, P < 0.01) and an increase in vigor (32.3%, P < 0.01). Interestingly, the control group also showed a decrease in fat mass (8.6%) without any treatment, highlighting a potential area for further investigation.

The findings of this pilot study suggest that the supplementation of guggulsterone phosphate salt compound, combined with regular exercise, may lead to a significant reduction in body weight and fat mass in overweight individuals. Additionally, the improvement in mood states, particularly the decrease in fatigue and increase in vigor, indicates the potential psychological benefits associated with this supplement. Further comprehensive research with a larger sample size and longer duration is warranted to confirm these initial observations and provide a deeper understanding of the effects of guggulsterone phosphate on body composition and mood in overweight adults.